Stimulatory action of cyclooxygenase inhibitors on hematopoiesis: A review

Molecules

Volumn 17, Issue 5, 2012, Pages 5615-5625

  Hofer, Michal ^a   Pospíŝil, Milan ^a   Hoferová, Zuzana ^a   Weiterová, Lenka ^a   Komurková, Denisa ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

Cyclooxygenase inhibition; Cycloxygenase 2 inhibitors; Hematopoiesis; Myelosuppression; Prostaglandins

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL; BIOSYNTHESIS; BLOOD; DRUG EFFECT; FEEDBACK SYSTEM; GAMMA RADIATION; HEMATOPOIESIS; HUMAN; METABOLISM; MOUSE; MYELOPOIESIS; RADIATION EXPOSURE; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; FEEDBACK, PHYSIOLOGICAL; GAMMA RAYS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HUMANS; MICE; MYELOPOIESIS; THIAZINES; THIAZOLES;

EID: 84861494748     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17055615     Document Type: Review

References (87)

1. Kaushansky, K.; Lichtman, M.; Beutler, E.; Kipps, T.; Prchal, J.; Seligsohn, U. Williams Hematology, 8th ed.; McGraw-Hill, Inc.: New York, NY, USA, 2010.
2. Zion, L.I. Hematopoiesis: A Developmental Approach; Oxford University Press: New York, NY, USA, 2001.
3. Brady, R.H.; Serhan, C.N. The prostaglandin, leukotrienes, lipoxins, and platele-activating factor. In Immunology and Inflammation, Basic Mechanisms and Clinical Consequences; McGraw-Hill, Inc.: New York, NY, USA, 1993; pp. 271-286.
4. Smith, W.L.; DeWitt, D.L.; Garavito, R.M. Cyclooxygenases: Structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 68, 145-182.
5. Garavito, R.M.; Mulichak, A.M. The structure of mammalian cyclooxygenases. Annu. Rev. Biophys. Biomol. Struct. 2003, 32, 183-206.
6. Gentile, P.; Byer, D.; Pelus, L.M. In vivo modulation of murine myelopoiesis following intravenous administration of prostaglandin E2. Blood 1983, 62, 1100-1107.
7. Pelus, L.M.; Broxmeyer, H.E.; Kurland, J.I.; Moore, M.A.S. Regulation of macrophage and granulocyte proliferation. Specificities of prostaglandin E and lactoferin. J. Exp. Med. 1979, 150, 277-292.
8. Boorman, G.A.; Luster, M.I.; Dean, J.H.; Luebke, R.W. Effect of indomethacin on the bone marrow and immune system of the mouse. J. Clin. Lab. Immunol. 1982, 7, 119-126.
9. Kurland, J.; Moore, M.A.S. Modulation of hemopoiesis by prostaglandins. Exp. Hematol. 1977, 5, 357-373.
10. Fontagné, J.; Adolphe, M.; Semichon, M.; Zizine, L.; Lechat, P. Effect of in vivo treatment with indomethacin on mouse granulocyte-macrophage colony-forming cells in culture (CFUc). Possible role of prostaglandins. Exp. Hematol. 1980, 8, 1157-1164.
11. Pelus, L.M. Modulation of myelopoiesis by prostaglandin E2: Demonstration of a novel mechanism of action in vivo. Immunol. Res. 1989, 8, 176-184.
12. Maravic, M.; Berge, C.; Daures, J.P.; Boissier, M.C. Practices for managing a flare of long-standing rheumatoid arthritis: Survey among French rheumatologists. Clin. Exp. Rheumatol. 2005, 23, 36-42.
13. Harris, R.E.; Beebe-Donk, J.; Doss, H.; Doss, D.B. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade. Oncol. Rep. 2005, 13, 559-583.
14. Pereg, D.; Lishner, M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J. Int. Med. 2005, 248, 115-123.
15. Fehér, I.; Gidáli, J. Prostaglandin E2 as stimulator of haemopoietic stem cell proliferation. Nature 1974, 247, 550-551.
16. North, T.E.; Goessling, W.; Walkley, C.R.; Lengerke, C.; Kopani, K.R.; Lord, A.M.; Weber, G.J.; Bowman, T.V.; Jang, I.H.; Grosser, T.; et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007, 447, 1007-1011.
17. Hogatt, J.; Singh, P.; Sampath, J.; Pelus, L.M. Prostaglandin E-2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 2009, 113, 5444-5455.
18. Frölich, J.C. A classification of NSAIDs according to the relative inhibition of cyclooxygenase insoenzymes. Trends Pharmacol. Sci. 1997, 18, 30-34.
19. Simmons, D.L.; Botting, R.M.; Hla, T. Cyclooxygenase isoenzymes: The biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 2004, 56, 387-437.
20. Smith, W.L.; Urade, Y.; Jakobsson, P.-J. Enzymes of the cyclooxygenase pathways of prostanoid synthesis. Chem. Rev. 2011, 111, 5821-5865.
21. Crofford, L.J.; Lipsky, P.E.; Brooks, P.; Abramson, S.B.; Simon, L.S.; van de Putte, L.B.A. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum. 2000, 43, 4-13.
22. Lanas, A.; Panés, J.; Piqué, J.M. Clinical implications of COX-1 and/or COX/2 inhibition for the distal gastrointestinal tract. Curr. Pharm. Des. 2003, 9, 2253-2266.
23. Niho, Y.; Niiro, H.; Tanaka, Y.; Nakshima, H.; Otsuka, T. Role of IL-10 in the crossregulation of prostaglandins and cytokines in monocytes. Acta Haematol. 1998, 99, 165-170.
24. Takahashi, H.K.; Iwagaki, H.; Tamura, R.; Xue, D.; Sano, M.; Mori, S.; Yoshino, T.; Tanaka, N.; Nishibori, M. Unique regulation profile of prostaglandin E-1 on mononuclear cells. J. Pharmacol. Exp. Therap. 2003, 307, 1188-1195.
25. Chang, D.M.; Baptiste, P.; Chur, P.H. The effect of antirheumatic drugs on interleukin-1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes. J. Rheumatol. 1990, 17, 1148-1157.
26. Lozanski, G.; Ballou, S.P.; Kushner, I. Effect of flurbiprofen on cytokine production by human monocytes and U-937 and THP-1 cell-lines. J. Rheumatol. 1992, 19, 921-926.
27. Estrov, Z.; Resnitzky, P. Enhancement of hemopoietic stem cell proliferation by prostaglandin inhibitor drugs. Exp. Hematol. 1983, 11, 802-809.
28. Boorman, G.A.; Luster, M.I.; Dean, J.H.; Luebke, R.W. Effect of indomethacin on the bone marrow and immune system of the mouse. J. Clin. Lab. Immunol. 1982, 7, 119-126.
29. Taniguchi, K.; Koga, Y.; Kato, M.; Nomoto, K. The in vivo regulation of splenic T cell population by the prostaglandin-mediated system. J. Clin. Lab. Immunol. 1984, 14, 195-203.
30. Kalaidjieva, V. Modulation of erythropoiesis in rat bone marrow erythroblastic islands by cyclooxygenase inhibition. Gen. Pharmacol. 1999, 32, 423-428.
31. Hofer, M.; Pospíšil, M. Stimulated recovery of perturbed haematopoiesis by inhibition of prostaglandin production-Promising therapeutic strategy. Cent. Eur. J. Biol. 2006, 1, 584-593.
32. Furuta, Y.; Hunter, N.; Barkley, T.; Hall, E.; Milas, L. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res. 1988, 48, 3008-3013.
33. Kozubík, A.; Pospíšil, M.; Netíková, J. The stimulatory effect of single-dose pre-irradiation administration of indomethacin and dicofenac on hematopoietic recovery in the spleen of gamma-irradiated mice. Stud. Biophys. 1989, 131, 93-101.
34. Nishiguchi, I.; Furuta, Y.; Hunter, N.; Murray, D.; Milas, L. Radioprotection of haematopoietic tissue by indomethacin. Radiat. Res. 1990, 122, 188-192.
35. Kozubík, A.; Hofmanová, J.; Holá, J.; Netíková, J. The effect of nordihydroguairetic acid, an inhibitor of prostaglandin and leukotriene biosynthesis, on hematopoiesis of gamma-irradiated mice. Exp. Hematol. 1993, 21, 138-142.
36. Pospíšil, M.; Netíková, J.; Kozubík, A. Enhancement of haemopoietic recovery by indomethacin after sublethal whole-body gamma irradiation. Acta Radiol. Oncol. 1986, 25, 195-198.
37. Pospíšil, M.; Netíková, J.; Kozubík, A.; Pipalová, I. Effect of indomethacin, diclofenac sodium and sodium salicylate on peripheral blood cell counts in sublethally gamma-irradiated mice. Strahlenther. Onkol. 1989, 165, 627-631.
38. Serushago, B.A.; Tanaka, K.; Koga, Y.; Taniguchi, K.; Nomoto, K. Positive effects of indomethacin on restoration of splenic nucleated cell population in mice given sublethal irradiation. Immunopharmacology 1987, 14, 21-26.
39. Sklobovskaya, I.E.; Zhavoronkov, L.P.; Dubovik, R.V. Haemostimulating efficiency of prostaglandin biosynthesis inhibitors in conditions of fractionated irradiation (in Russian). Radiobiologiya 1986, 26, 185-188.
40. Hofer, M.; Pospíšil, M.; Pipalová, I. Radioprotective effects of flurbiprofen. Folia Biol. (Praha) 1996, 42, 267-269.
41. Hofer, M.; Pospíšil, M.; Pipalová, I.; Holá, J. Modulation of haemopoietic radiation response of mice by diclofenac in fractionated treatment. Physiol. Res. 1996, 45, 213-220.
42. Mišúrová, E.; Kropácová, K.; Chlebovský, O.; Pado, D. The effect of indomethacin on nucleic acids in blood, hemopoietic and lymphoid tissues in continuously irradiated rats. Neoplasma 1989, 36, 541-547.
43. Kozubík, A.; Pospíšil, M.; Viklická, Š.; Tkadlecek, L.; Netíková, J. Effect of indomethacin on the proliferation and differentiation activity in the haemopoietic system of lethally irradiated mice after syngeneic bone marrow transplantation. Folia Biol. (Praha) 1987, 33, 418-423.
44. Kozubík, A.; Hofmanová, J.; Pospíšil, M.; Netíková, J.; Holá, J.; Lojek, A. Effects of drugs inhibiting prostaglandin or leukotriene biosynthesis on postirradiation haematopoiesis in mice. Int. J. Radiat. Biol. 1994, 65, 369-377.
45. Hofer, M.; Hoferová, Z.; Fedorocko, P.; Macková, N.O. Hematopoiesis-stimulating and anti-tumor effects of repeated administration of diclofenac in mice with transplanted fibrosarcoma cells. Physiol. Res. 2002, 51, 629-632.
46. Pospíšil, M.; Hofer, M.; Pipalová, I.; Viklická, Š.; Netíková, J.; Šandula, J. Enhancement of hematopoietic recovery in gamma-irradiated mice by the joint use of diclofenac, an inhibitor of prostaglandin production, and glucan, a macrophage activator. Exp. Hematol. 1992, 20, 891-895.
47. Hofer, M.; Pospíšil, M.; Viklická, Š.; Vacek, A.; Pipalová, I.; Bartonícková, A. Hematopoietic recovery in repeatedly irradiated mice can be enhanced by a repeatedly administered combination of diclofenac and glucan. J. Leukoc. Biol. 1993, 53, 185-189.
48. Fedorocko, P. Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) promotes hematopoietic recovery in irradiated mouse. Int. J. Radiat. Biol. 1994, 65, 465-475.
49. Fedorocko, P.; Macková, N.O. Combined modality radioprotection: Enhancement of survival and hematopoietic recovery by the joint use of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and indomethacin. Int. J. Immunopharmacol. 1996, 18, 329-337.
50. Macková, N.O.; Fedorocko, P. Effect of liposomal muramyl tripeptide phosphatidylethanolamine and indomethacin on hematopoietic recovery in irradiated mice. Physiol. Res. 2002, 51, 511-521.
51. Fedorocko, P.; Macková, N.O.; Brezani, P.; Kopka, M. Administration of the bacterial extract Broncho-Vaxom(R) enhances radiation recovery and myelopoietic regeneration. Immunopharmacology 1994, 28, 163-170.
52. Fedorocko, P.; Macková, N.O. Radioprotective effects of combination of bronchovaxom, a macrophage activator, and indomethacin, an inhibitor of prostaglandin production: Relationships to myelopoiesis. Eur. J. Haematol. 1996, 56, 54-61.
53. Sklobovskaya, I.E.; Zhavoronkov, L.P. The combined effect of chemical radioprotective agents and prostaglandin biosynthesis inhibitors on postirradiation recovery of mouse haemopoiesis (in Russian). Radiobiologiya 1986, 26, 61-64.
54. Kozubík, A.; Pospíšil, M.; Netíková, J. Enhancement of haemopoietic recovery in sublethally gamma-irradiated mice by the joint use of indomethacin and cystamine. Folia Biol. (Praha) 1990, 36, 291-300.
55. Kozubík, A.; Pospíšil, M.; Netíková, J. Possibilities of the combined use of non-steroidal anti-inflammatory drugs and sulfyhdryl componds in radioprotection. Strahlenther. Onkol. 1991, 167, 186-190.
56. Besa, P.C.; Hunter, N.R.; Milas, L. Improvement in radiotherapy for a murine sarcoma by indomethacin plus WR-2721. Radiat. Res. 1993, 135, 93-97.
57. Fontagné, J.; Bertin, R.; Demarco, F.; Zizine, L.; Adolphe, M.; Portet, R.; Lechat, P. In vivo effects of indomethacin and cyclophosphamide on CFU-GM proliferation and cyclic-nucleotide levels in bone marrow of mice. Biomed. Pharmacol. 1983, 37, 452-457.
58. Nickevich, D.A.; Young, M.R.; Ellis, N.K.; Wepsich, H.T. Stimulation of hematopoiesis in untreated and cyclophosphamide-treated mice by the inhibition of prostaglandin synthesis. J. Immunopharmacol. 1986, 8, 299-313.
59. O'Reilly, M.; Gamelli, R.L. Indomethacin augments granulocyte-macrophage colony-stimulating factor-induced hematopoiesis following 5-FU treatment. Exp. Hematol. 1990, 18, 974-978.
60. Wang, J.Y.; Yamasaki, S.; Takeuchi, K.; Okabe, S. Delayed healing of acetic acid-induced gastric ulcers in rats by indomethacin. Gastroenterology 1989, 96, 393-402.
61. Akarca, U.S. Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs. Curr. Pharm. Des. 2005, 11, 1779-1793.
62. Mahmud, T.; Scott, D.L.; Bjarnason, I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann. Rheum. Dis. 1996, 55, 211-213.
63. Floersheim, G.L. Allopurinol, indomethacin and riboflavin enhance radiation lethality in mice. Radiat. Res. 1994, 139, 240-247.
64. Hofer, M.; Pospíšil, M.; Tkadlecek, L.; Viklická, Š.; Pipalová, I. Low survival of mice following lethal gamma-irradiation after administration of inhibitors of prostaglandin synthesis. Physiol. Res. 1992, 41, 157-161.
65. Wallace, J.L.; Reuter, B.; Cicala, C.; McKnight, W.; Grisham, M.B.; Cirino, G. Novel nonsteroidal antiinflammatory drug derivatives with markedly reduced ulcerogenic properties in rats. Gastroenterology 1994, 107, 173-179.
66. Juchelková, L.; Hofer, M.; Pospíšil, M.; Pipalová, I. Radioprotective effects of flurbiprofen and its nitroderivative. Physiol. Res. 1998, 47, 73-80.
67. Michalowski, A.S. On radiation damage to normal tissues and its treatment. II. Anti-inflammatory drugs. Acta Oncol. 1994, 33, 139-157.
68. Shoup, M.; He, L.K.; Liu, H.; Shankar, R.; Gamelli, R. Cyclooxygenase-2 inhibitor NS-398 improves survival and restores leukocyte counts in burn infection. J. Trauma Inj. Infect Crit. Care 1998, 45, 215-220.
69. Ogino, K.; Hatanaka, K.; Kawamura, M.; Ohno, T.; Harada, Y. Meloxicam inhibits prostaglandin E2 generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach. Pharmacology 2000, 61, 244-250.
70. Hofer, M.; Pospíšil, M.; Znojil, V.; Holá, J.; Vacek, A.; Weiterová, L.; Štreitová, D.; Kozubík, A. Meloxicam, a cyclooxygenase-2 inhibitor, supports hematopoietic recovery in gamma-irradiated mice. Radiat. Res. 2006, 166, 556-560.
71. Hofer, M.; Pospíšil, M.; Znojil, V.; Holá, J.; Vacek, A.; Štreitová, D. Meloxicam, an inhibitor of cyclooxygenase-2, increases the level of serum G-CSF and might be usable as an auxiliary means in G-CSF therapy. Physiol. Res. 2008, 57, 307-310.
72. Hofer, M.; Pospíšil, M.; Holá, J.; Vacek, A.; Štreitová, D.; Znojil, V. Inhibition of cyclooxygenase 2 in mice increases production of G-CSF and induces radioprotection. Radiat. Res. 2008, 170, 566-571.
73. Jiao, W.; Kiang, J.G.; Cary, L.; Elliot, T.B.; Pellmar, T.C.; Ledney, G.D. COX-2 inhibitors are contraindicated for treatment of combined injury. Radiat. Res. 2009, 172, 686-697.
74. Hofer, M.; Pospíšil, M.; Dušek, L.; Hoferová, Z.; Weiterová, L. A single dose of an inhibitor of cyclooxygenase 2, meloxicam, administered shortly after irradiation increases survival of lethally irradiated mice. Radiat. Res. 2011, 176, 269-272.
75. Anning, P.B.; Coles, B.; Morton, J.; Wang, H.; Uddin, J.; Morrow, J.D.; Dey, S.K.; Marnett, L.J.; O'Donnell, V.B. Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood 2006, 108, 4059-4062.
76. Staerkel, P.; Horsmans, Y. Meloxicam-induced liver toxicity. Acta Gastroenterol. Belg. 1999, 62, 255-256.
77. Hérodin, F.; Drouet, M. Cytokine-based treatment of accidentally irradiated victims and new approaches. Exp. Hematol. 2005, 33, 1071-1080.
78. Hérodin, F.; Drouet, M. Myeloprotection following cytotoxic damage: The sooner, the better. Exp. Hematol. 2008, 36, 769-770.
79. Hofer, M.; Pospíšil, M.; Dušek, L.; Hoferova, Z.; Weiterova, L. Inhibition of cyclooxygenase-2 promotes the stimulatory action of adenosine A3 receptor agonist in sublethally ?-irradiated mice. Biomed. Pharmacother. 2011, 65, 427-431.
80. Sugimoto, Y.; Fukada, Y.; Mori, D.; Tanaka, S.; Yamane, H.; Okuno, Y.; Deai, K.; Tsuchiya, S.; Tsujimoto, G.; Ichikawa, A. Prostaglandin E-2 stimulated granulocyte colony-stimulating factor production via the prostanoid EP2 receptor in mouse peritoneal neutrophils. J. Immunol. 2005, 175, 2606-2612.
81. Goldman, A.P.; Williams, C.S.; Sheng, H.M.; Lamps, L.W.; Williams, V.P.; Pairet, M.; Morrow, J.D.; DuBois, R.N. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 1998, 19, 2195-2199.
82. Hussey, H.J.; Tisdale, M.J. Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model. Int. J. Cancer 2000, 87, 95-100.
83. Kern, M.A.; Schöneweiβ, M.M.; Sahi, D.; Bahlo, M.; Haugg, A.M.; Kasper, H.U.; Dienes. H.P.; Käferstein, H.; Breuhahn, K.; Schirmbacher, P. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 2004, 25, 1193-1199.
84. Kuipers, G.K.; Slotman, B.J.; Wedekind, L.E.; Stoter, T.R.; van der Berg, J.; Sminia, P.; Vincent, M.; Lafleur, M. Radiosenzitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: Independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration. Int. J. Radiat. Biol. 2007, 83, 677-685.
85. Ayakawa, S.; Shibamoto, Y.; Sugie, C.; Ito, M.; Ogino, H.; Tomito, N.; Kumagai, M.; Murakami, H.; Sawa, H. Antitumor effects of a cyclooxygenase-2 inhibitor, meloxicam, alone or in combination with radiation and/or 5-fluorouracil in cultured tumor cells. Mol. Med. Rep. 2009, 2, 621-625.
86. Crook, J.; Patil, N.; Wallace, K.; Borg, J.; Zhou, D.; Ma, C.; Pond, G. A phase III randomized trial of the timing of meloxicam with iodine-125 prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77, 496-501.
87. Lefrere, F.; Makke, J.; Fermand, J.P.; Marolleau, J.P.; Dal Cortivo, L.; Alberti, C.; Mouton, V.; Benbunan, M.; Miclea, J.M. Blood stem cell collection using chemotherapy with or without G-CSF: Experience in 52 patients with multiple myeloma. Bone Marrow Transplant. 1999, 24, 463-466.